Trial Profile
A Study to Evaluate the Long-Term Outcomes of Eculizumab in Positive Crossmatch Kidney Transplant (+XMKTx) Recipients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2015
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 30 Dec 2015 New trial record